Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type
% Q' f, f- O; A: BNOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9
8 y0 b& Q: [0 m5 P" r3 I# q( X+ Author Affiliations
7 i) B/ O2 [+ E; O+ ^
; x* s z7 U# k8 J: s/ d4 ~1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan 6 L& Z) N! h" q
2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
1 x/ o! G7 ^$ O: t- r) \8 t7 w3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan ; m8 o0 \$ E, i+ G9 C( u
4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan
. @. L' G7 T' a/ i$ F. u% W6 _5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan 0 x, N: Z" T6 Y% }: j
6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan 5 u# Z5 Q5 N( v. P7 G
7Kinki University School of Medicine, Osaka 589-8511, Japan
6 O$ H p5 l# X: E4 v( ?& H8Izumi Municipal Hospital, Osaka 594-0071, Japan
* b6 a1 Y4 S( f9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan
~' R9 H* U# }0 bCorrespondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp # w% x7 d4 U) c+ N
AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type.
: ^/ D* ^+ n1 G2 k5 l* t+ W* J. g
: D% J$ `6 r0 N' U |